孕妇被排除在紧急疫苗临床试验之外:2009至2019年临床试验方案与报告的系统评价
该系统评价检索2009至2019年H1N1流感、MERS-CoV、寨卡和埃博拉病毒病疫情期间启动的II期和III期疫苗临床试验方案,共纳入84个方案。仅8个方案明确纳入孕妇,其中3个有发表结果;孕妇在疫情期疫苗临床试验中代表性不足,导致妊娠相关结局报告不足。
要点
- 84个疫苗试验方案中仅8个明确纳入孕妇,其中3个有发表结果。
- 共报告411例妊娠结局,其中293例来自3个纳入孕妇且有结果的研究。
- 所有有结果的临床试验共报告71例与妊娠相关的严重不良事件。
核心结论
- 孕妇在疫情期疫苗临床试验中代表性不足,导致妊娠相关结局报告不足,并使孕妇和新生儿缺乏对传染病的保护。
研究设计与样本
- 系统评价检索2009至2019年H1N1流感、中东呼吸综合征冠状病毒(MERS-CoV)、寨卡和埃博拉病毒病(EVD)疫情期间启动的II期和III期疫苗临床试验方案,数据来源为ClinicalTrials.gov、泛非临床试验注册中心(PACTR)和世界卫生组织国际临床试验注册平台(ICTRP)指示的所有主要注册中心,并通过PubMed定位已发表研究。
- 共识别96个疫苗临床试验方案,最终纳入84个进行分析;筛选中排除5条记录(摘要不相关),全文评估排除7条(1项治疗性药物试验、3项仅纳入老年人、3项仅纳入儿童/青少年)。
- MERS-CoV和寨卡病毒疫苗无合格试验。
主要发现
- 8个方案明确纳入孕妇,其中3个为已完成试验并有发表结果。
- 2项研究报告了偶然妊娠及孕妇参与者的结局,10项报告了与妊娠相关的严重不良事件但未提及偶然妊娠总数。
- 共报告411例记录的妊娠结局,其中293例来自3个纳入孕妇且有结果的研究。
- 所有有结果的临床试验共报告71例与妊娠相关的严重不良事件。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Existing ethics guidance and regulatory requirements emphasize the need for pregnancy-specific safety and efficacy data during the development of vaccines in health emergencies. Our objective was to conduct a systematic review of vaccine clinical trials during active epidemic periods. METHODS: We searched for Phase II and Phase III vaccine clinical trials initiated during the H1N1 influenza, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), Zika, and Ebola virus disease (EVD) outbreaks from 2009 to 2019. Data were extracted from clinical trial protocols identified in the following registries: ClinicalTrials.gov, Pan African Clinical Trial Registry (PACTR), and all primary registries indicated by the World Health Organization's International Clinical Trials Registry Platform (ICTRP). Published studies from registered clinical trials were located through PubMed. Data was extracted on eligibility criteria and pregnancy outcomes. Data from this study is available in the Center for Open Science Data Repository: https://osf.io/nfk2p/?view_only=47deb3b206724af9b46c9c0c0083a267. RESULTS: We identified 96 vaccine clinical trial protocols and included 84 in analysis. 5 records were excluded in screening for irrelevant abstracts, 7 were excluded in full-text assessment (1 for a therapeutic drug trial, 3 for enrolling elderly adults only, 3 for enrolling children/adolescents only). There were no eligible trials for MERS-CoV or Zika virus vaccines. Overall, 8 protocols explicitly included pregnant people; of these, 3 were completed trials with published results. Incidental pregnancies and outcomes of pregnant participants were reported in 2 studies, 10 studies reported serious adverse events related to pregnancy without mentioning total incidental pregnancies. A total of 411 recorded pregnancy outcomes were reported, with 293 from the 3 pregnancy-eligible studies with results. 71 serious adverse events pertaining to pregnancy were reported from all clinical trials with results. CONCLUSION: Pregnant people are underrepresented in vaccine clinical trials conducted during outbreaks, resulting in underreporting of pregnancy-related outcomes and a lack of protection for pregnant people and neonates from infectious diseases.
引用
- Minchin J, Harris GH, Baumann S, et al. Exclusion of pregnant people from emergency vaccine clinical trials: A systematic review of clinical trial protocols and reporting from 2009 to 2019. Vaccine. 2023. PMID: 37442686. doi:10.1016/j.vaccine.2023.06.073
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。